In Search for Titanocene Complexes with Improved Cytotoxic Activity: Synthesis, X-Ray Structure, and Spectroscopic Study of Bis(η5-cyclopentadienyl)difluorotitanium(IV) by Koleros, Elias et al.
Hindawi Publishing Corporation
Bioinorganic Chemistry and Applications




Activity:Synthesis,X-Ray Structure, andSpectroscopicStudy of
Bis(η5-cyclopentadienyl)diﬂuorotitanium(IV)
Elias Koleros,1 TheocharisC.Stamatatos,1 VassilisPsycharis,2 CatherineP. Raptopoulou,2
Spyros P. Perlepes,1 andNikolaos Klouras1
1Department of Chemistry, University of Patras, 26504 Patras, Greece
2National Center of Scientiﬁc Research, “Demokritos” (NCSR), Institute of Materials Science, Aghia Paraskevi, 15310 Attikis, Greece
Correspondence should be addressed to Nikolaos Klouras, n.klouras@chemistry.upatras.gr
Received 27 March 2010; Accepted 3 May 2010
Academic Editor: Evy Manessi-Zoupa
Copyright © 2010 Elias Koleros et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The 1 : 2 reaction of [Ti(η5-C5H5)2Cl2] and AgF in CHCl3/H2O yielded the ﬂuoro analog [Ti(η5-C5H5)2F2]( 1) in almost
quantitative yield (C5H5 is the cyclopentadienyl group). The coordination about the Ti
IV atom formed by two ﬂuoro ligands
and the centroids of the cyclopentadienyl rings is distorted tetrahedral. The compound crystallizes in the orthorhombic space
group C2cm. The lattice constants are a = 5.9055(4),b = 10.3021(5),c = 14.2619(9) ˚ A, and α = β = γ = 90
◦.T h ec o m p l e xh a s
been characterized by elemental analyses and spectroscopic (IR, 1H NMR) data. A structural comparison of the four members of
the [Ti(η5-C5H5)2X2] family of complexes (X = F,Cl,Br,I) is attempted.
1.Introduction
One of the ﬁrst metal complexes discovered to exhibit
biological activity has been cisplatin, [Pt(NH3)2Cl2][ 1]. It
is considered as one of the most eﬃcient drugs for the
treatment of certain types of cancer; however, drug toxicity
and resistance limit its utilization for a broader range of
diseases. In recent years, there has been a growing inter-
est in the development of nonplatinum-based anticancer
therapeutics. The main goal is to increase the variety of
potential drugs, which may lead to higher activities enabling
the administration of lower doses, attack of diﬀerent types
of tumour cells, solution of drug resistance problems, better
selectivity and to lower toxicity. Non-platinum complexes
may introduce numerous options for coordination numbers
and geometries, oxidation states, aﬃnity for certain types
of biological ligands, and so forth, and may thus operate
by diﬀerent mechanisms. One class of such complexes are
metallocene dihalides.
Metallocene dihalides, [M(η5-C5H5)2X2]( M= Ti, V, Nb,
Mo, Re; X = halide ligand; C5H5 = Cp, the cyclopentadienyl
group), are a relatively new class of small hydrophobic
organometallic anticancer agents that exhibit antitumour
activities against cancer cell lines, such as leukaemias P388
and L1210, colon 38 and Lewis lung carcinomas, B16
melanoma, solid and ﬂuid Ehrlich ascites tumours and
also against human colon, renal and lung carcinomas
transplantedintoathymicmice[2–5].Titanocenedichloride,
[Ti(η5-C5H5)2Cl2], is the most widely studied metallocene
compound as a cytotoxic anticancer agent, which means
that it can selectively kill cancer cells, and was used in
phase I and II clinical trials [6–13]. However, the eﬃcacy
of [Ti(η5-C5H5)2Cl2] in phase II clinical trials in patients
with metastatic renal cell carcinoma [12]o rm et a s t a ti cb r e a s t
cancer [13] was too low to be pursued. As titanium is present
in many biomaterials, such as in food in the form of a
whitening pigment, it is not unreasonable to conceive that it
may be incorporated into drugs and into living systems, with
particularly low toxicity [14].
In 2008, a novel class of substituted titanocene dichlo-
rides, the so-called “benzyl-substituted titanocenes”, with
improved cytotoxic activity were developed and tested for
their potential application as anticancer drugs [15]. The
cytotoxic activity can also be inﬂuenced by substitution2 Bioinorganic Chemistry and Applications
of the two chloride ligands. More recently, Huhn and co-
workers reported the synthesis and cytotoxicity of selected
benzyl-substituted ﬂuorotitanocene derivatives that showed
a cytotoxic activity 3–5 fold higher than that of the respective
dichlorides [16]. In the same paper, the X-ray structure
analysis of two of the titanocene diﬂuoride derivatives was
also described. The prototype of the latter compounds
is titanocene diﬂuoride, [Ti(η5-C5H5)2F2], which itself (i)
exhibits strong antitumor, anti-inﬂammatory and anti-
arthritic activity as well as immunosuppressant eﬀects [17,
18], (ii) reduces signiﬁcantly the rates of crystal growth
of hydroxyapatite (the model compound for the inorganic
component of bones and teeth, observed in pathological
calciﬁcations of the articular cartilage) [19], and (iii) is an
eﬀective catalyst for the reduction of lactones and imines,
reductive-deoxygenative coupling of amides, hydrogenation
of oleﬁns, and deﬂuorination of saturated perﬂuorocarbons
[20].
Surprisingly, the crystal structure of bis(η5-cyclopenta-
dienyl)diﬂuorotitanium(IV) is not known. In the present
work, we describe the ﬁrst X-ray diﬀraction study of [Ti(η5-
C5H5)2F2], providing structural data which will probably
be important in structure-activity investigations of new
titanocene diﬂuorides, a promising class in terms of medical
applications.
2. Experiments
Reagents and solvents were purchased from commercial
sources, and were puriﬁed (where necessary) and dried
before use by standard procedures. The starting titanocene
dichloride, [Ti(η5-C5H5)2Cl2], was synthesized under an
argon atmosphere using dried THF by the method of
Wilkinson and Birmingham [21] and recrystallized from
boiling toluene. All manipulations were performed under
aerobic conditions. Microanalyses (C, H) were performed by
the University of Patras (Greece) Microanalytical Laboratory
using an EA 1108 Carlo Erba analyzer. IR spectra (4000–
450cm−1) were recorded on a Perkin-Elmer 16 PC FT-
spectrometer with samples prepared as KBr pellets. The
1H NMR spectrum of the complex in CDCl3 was recorded
with a Bruker Avance 400 MHz spectrometer; chemical
shifts are reported relative to tetramethylsilane. Conductivity
measurements were carried out at 25
◦C using an Ehrhardt-
Metzger, type L21, conductivity bridge.
[Ti(η5-C5H5)2F2]( 1) was synthesized in a plastic bot-
tle from a solution of the dichloride, [Ti(η5-C5H5)2Cl2]
(5mmol), in CHCl3 by adding a freshly prepared aqueous
solution of AgF (10mmol) according to the procedure
described in [22]. The reaction mixture was shaken vig-
orously for 20 minutes at room temperature. During this
time, the colour of the organic phase changed from red
to orange and ﬁnally to yellow. The yellow CHCl3 phase
was separated from the aqueous phase, containing the white
precipitate of AgCl, through a separatory funnel and ﬁltered.
Condensation of the yellow ﬁltrate under reduced pressure
gave a ﬂuﬀy lemon-yellow solid that was dried in vacuo over
silica gel and recrystallized from toluene. Yield 90% and m.p.
235
◦C (dec.) Lemon-yellow, needle-like crystals of 1 suitable
Table 1: Crystallographic data and structure reﬁnement for
complex 1.
Empirical formula C40H40Ti4F8
Formula weight (g mol−1) 864.32
Colour and habit Yellow prisms




a, ˚ A 5.9055(4)
b, ˚ A 10.3021(5)




V, ˚ A3 867.66(9)
Z 1
ρ,M gm −3 1.654
T, K 160(2)
Radiation (˚ A) Cu Kα (λ = 1.54178)
μ,m m −1 8.207
F(000) 440
θ range (◦) 8.61–59.99
Index ranges, ◦ –6 ≤ h ≤ 6
–11 ≤ k ≤ 11
–14 ≤ l ≤ 12
Measured reﬂections 2894
Unique reﬂections 613 (Rint = 0.0947)
Reﬂections used [I > 2σ(I)] 535
Parameters reﬁned 60
GoF (on F 2) 1.100
R1a [I > 2σ(I)] 0.0668
w R2b [I > 2σ(I)] 0.1469
(Δρ)max /(Δρ)min,e˚ A−3 1.183/−0.680








for X-ray analysis were obtained by vapour diﬀusion of
petroleum ether into a CHCl3 solution of the product placed
in an H-shaped tube. Anal. Calc. for C10H10F2Ti (216.08):
C, 55.59; H, 4.66. Found: C, 55.28; H, 4.62. Selected IR data
(KBr, cm−1): 3108 (s), 1442 (s), 1362 (w), 1016 (s), 874 (m),
822 (vs), 610 (w), 564 (s), 539 (m). 1H NMR (400 MHz,
CDCl3): δ 6.53 (t).
2.1. X-Ray Crystallographic Studies. A yellow prismatic crys-
tal of 1 was taken directly from the mother liquid and
immediately cooled to −113
◦C. Diﬀraction measurements
were made on a Rigaku R-AXIS SPIDER Image Plate diﬀrac-
tometer using graphite monochromated Cu Kα radiation.
Data collection (ω-scans) and processing (cell reﬁnement,
data reduction and empirical absorption correction) were
performed using the CRYSTALCLEAR program package
[23]. Important crystal data and parameters for data collec-
tion and reﬁnement are listed in Table 1. The structure wasBioinorganic Chemistry and Applications 3
Table 2: Selected bond lengths (˚ A) and angles (◦)f o rc o m p l e x1.a
Ti-F(1) 1.853(4) Ti-C(3) 2.363(9)
Ti-F(2) 1.859(4) Ti-C(4) 2.365(10)
Ti-C(1) 2.375(11) Ti-C(5) 2.396(11)
Ti-C(2) 2.400(11) Ti-Cp 2.066
C(1)-C(2) 1.358(15) C(4)-C(5) 1.386(14)
C(2)-C(3) 1.396(14) C(5)-C(1) 1.390(15)
C(3)-C(4) 1.411(16) mean C-C 1.388
F(1)-Ti-F(2) 96.0(2) F(1)-Ti-Cp 107.30
Cp-Ti-Cp
  128.53 F(2)-Ti-Cp 106.46
C(1)-C(2)-C(3) 108.6(10) C(4)-C(5)-C(1) 107.5(10)
C(2)-C(3)-C(4) 106.8(7) C(5)-C(1)-C(2) 109.2(13)
C(3)-C(4)-C(5) 107.8(8) Aver. C-C-C 108.0
aPrimed atoms are related to the unprimed ones by the symmetry operation x, y,1 / 2 - z.
solved by direct methods using SHELXS-97 [24]a n dr e ﬁ n e d
by full-matrix least-squares techniques on F2 with SHELXL-
97 [25]. Hydrogen atoms of the cyclopentadienyl (Cp) group
were introduced at calculated positions as riding on bonded
atoms. All non-H atoms were reﬁned anisotropically. In
the structure of 1, the carbon atoms of one of the two
Cp rings are disordered over symmetry-related positions.
CCDC 771089 contains the supplementary crystallographic
data for this paper. These data can be obtained free of
charge at http://www.ccdc.cam.ac.uk/conts/retrieving.hmtl
(or from the Cambridge Crystallographic Data Centre, 12
Union Road, Cambridge CB2 1EZ, UK; Fax: (internat.) ++
44-1223/336-033; E-mail: deposit@ccdc.cam.ac.uk).
3. Results andDiscussion
3.1. Synthetic Comments. T h et i t l ec o m p o u n dw a sﬁ r s t
prepared by Wilkinson and Birmingham in 1954 by dis-
solving the bromo analog, [Ti(η5-C5H5)2Br2], in hot 12
N hydroﬂuoric acid and heating on a steam-bath until
the solution was pale yellow in colour. On cooling, yellow
crystals were received which were recrystallized from 3 N
hydroﬂuoric acid solution [21]. Among the other published
in the literature methods, we selected that described by
Pink in his Thesis. The method uses AgF prepared in situ,
which gives the best yields in the shortest time [29]. The
preparation of 1 involves the reactions represented by the
stoichiometric equations (1)–(3):
2AgNO3 +2NaOH −→ Ag2O+2 N aN O 3 +H 2O, (1)


















+2 A gC l.
(3)
The two ﬁrst steps ((1)a n d( 2)) are necessary because AgF
decomposes upon staying. Experiments with commercial
AgF always lead to poor yields. Another method for a high-














Figure 1: Labeled PovRay representation of complex 1 with the
atom numbering scheme. Primes are used for symmetry-related
atoms. Colour scheme: Ti
IV, yellow; F, blue; C, gray; H, purple.
[30]andinvolvesthe1 : 2reactionof[Ti(η5-C5H5)2Cl2]and
the good ﬂuorinating agent {2-[(CH3)2NCH2]C6H4}(n-
Bu)2SnF in CH2Cl2.
Complex 1 is, like [Ti(η5-C5H5)2Cl2], a very stable
compound. It dissolves easily in common organic solvents
such as chloroform, methanol, benzene, toluene and is much
more soluble in water than are the other congener halides,
even at room temperature, without decomposition. A decent
watersolubilityisessentialforasatisfactorycytotoxicactivity
of titanium(IV) complexes. Its molar conductivity (H2O,
10−3 M, 25
◦C) is less than 5Scm2 mol−1. This means that,
in contrast to the other corresponding titanocene dihalides,
the ﬂuoride ligands in 1 are hydrolytically stable. In this case,
the water solubility and negligible molar conductivity could
be attributed to the formation of hydrogen bonds between
the electronegative F− ligands of 1 and the H2Om o l e c u l e s
rather than to a dissociation of the complex to species4 Bioinorganic Chemistry and Applications
Table 3: Comparison of some important molecular parameters (average values) for the four prototype titanocene dihalogenides, [Ti(η5-
C5H5)2X2].
Compound Ti–Cp
a (˚ A) Ti–X (˚ A) Cp–Ti–Cp (◦)X – T i – X ( ◦)R e f .
[Ti(η5-C5H5)2F2] 2.066 1.856 128.5 96.0 present work
[Ti(η5-C5H5)2Cl2] 2.059 2.364 131.0 94.5 [26]
[Ti(η5-C5H5)2Br2] 2.058 2.493 131.6 94.9 [27]
[Ti(η5-C5H5)2I2] 2.045 2.769 132.3 92.8 [28]
aCp = η5-cyclopentadienyl ring.
Table 4: Comparison of unit cell parameters for the four prototype titanocene dihalogenides, [Ti(η5-C5H5)2X2].
Compound a (˚ A) b (˚ A) c (˚ A) α (◦) β (◦) γ (◦) Crystal system Ref.
[Ti(η5-C5H5)2F2] 5.9055(4) 10.3021(5) 14.2616(9) 90 90 90 Orthorhombic present work
[Ti(η5-C5H5)2Cl2] 7.882(5) 19.478(10) 12.156(9) 90.46(2) 102.58(2) 143.49(2) Triclinic [26]
[Ti(η5-C5H5)2Br2] 7.872(5) 11.807(5) 12.310(3) 107.62(3) 100.83(4) 90.69(4) Triclinic [27]
[Ti(η5-C5H5)2I2] 13.426(4) 7.173(2) 13.096(4) 90 116.686(5) 90 Monoclinic [28]




Figure 2: Drawing of the crystalline packing of complex 1.
like [Ti(η5-C5H5)2(H2O)2]2+ and F−. The oxophilicity of
Ti
IV makes complexes of this metal ion with organic and
inorganicligandshighlysusceptibletohydrolysis.Complexes
of hydrolytic instability are not biologically active, probably
due to rapid formation of inactive aggregates [14].
3.2. Spectroscopic Characterization. The IR spectra of π-
bonded cyclopentadienyl metal complexes have been studied
[31–33]. In the IR spectrum of 1 the bands at 3108, 1442,
1016, 874/822 and 610 cm−1 can be assigned [31–33]t o
the ν(CH), ν(CC), δ(CH), π(CH) and δ(CCC) vibrational
modes, respectively. The bands at 564 and 539cm−1 are
assigned [32] to the ν1(A1)a n dν6(B1)( u n d e rC2V point




at δ = 6.53ppm corresponding to the equivalent protons
of the η5-C5H5 protons [31, 34]. The triplet character of
the signal is due to the small 3J coupling (1.7Hz) between
the cyclopentadienyl protons and the ﬂuoro nuclei in the
molecule [34].
3.3. Description of Structure. The molecular structure and a
crystal packing diagram of 1 are shown in Figures 1 and 2,
respectively. Bond lengths and angles are listed in Table 2.
The structure of 1 consists of isolated [Ti
IV(η5-
C5H5)2F2] molecules. The molecule has the familiar, dis-
torted tetrahedral shape found in the chloro [26], bromo
[27] and iodo [28] members of the [Ti
IV(η5-C5H5)2X2]
family of complexes. The distorted tetrahedral structure
arises if we consider the Cp ring centroids as each occupying
one coordination site around the metal ion. The cyclopenta-
dienyl centroid-titanium-cyclopentadienyl centroid angle is
128.53
◦, and the ﬂuorine-titanium-ﬂuorine angle is 96.0
◦.
The TiF2 group deﬁnes a symmetry plane and there is thus
one crystallographically independent Cp ligand. The plane
deﬁned by the Ti
IV atom and the centroids of the Cp rings
bisects the F-Ti-F bond angle. Thus, the molecule has a 2-
foldsymmetryaboutthelineofintersectionofthisplaneand
theplaneoftheF-Ti-Fbondangle;itspointgroupsymmetry
is C2v. The Cp ring is planar to ±0.019 ˚ A. The least-squares
planes of the two symmetry related Cp rings in the bent
(Cp)2Ti fragment of 1 form a dihedral angle of 53.49◦.T h e
two Cp rings exhibit a staggered conformation. The angle
between the normals to ring planes is 53.83◦.
The ﬁve Ti-C bond lengths range from 2.363(9) to
2.400(11) ˚ A. This narrow range establishes a distinct penta-
hapto coordination mode for each Cp ligand in 1.T h em e a n
Ti-C bond distance (2.380 ˚ A) is in agreement with the corre-
sponding values of other bis(cyclopentadienyl)titanium(IV)
complexes, for example, the value of 2.370 ˚ Ai n[ T i ( η5-
C5H5)2Cl2][ 26]. The Ti
IV-F bond distances [1.853(4),
1.859(4) ˚ A] are similar to those found in other 4-coordinate
titanium(IV) complexes containing terminal Ti-F bonds [16,
35, 36]. The C-C bond lengths in the Cp ring of 1 with
an average value of 1.388 ˚ A are within the usual rangeBioinorganic Chemistry and Applications 5
reported for organometallic complexes containing Cp− rings
[27].
Since the single-crystal, X-ray structures of all the four
membersofthe[Ti(η5-C5H5)2X2](X=F, Cl, Br, I) family are
now known, we feel it is interesting to compare some of their
important structural and crystallographic parameters. The
comparisons are presented in Tables 3 and 4,r e s p e c t i v e l y .
The average distance from the Ti
IV atom to the ring centroid
and the angle between the vectors from the metal center
to each of the ring centroids vary by less than 0.025 ˚ Aa n d
4◦, respectively, across the four complexes. The F-Ti-F angle
(96.0◦) is slightly wider than the corresponding X-Ti-X (X
= Cl, Br, I) angles (92.8–94.5◦) suggesting that electronic,
rather than steric, eﬀects inﬂuence this angle. The ﬂuoro
complex 1 has the largest X-Ti-X and the smallest Cp-Ti-Cp
angle. As expected, the average titanium-halogen distances
follow the sequence Ti-F < Ti-Cl < Ti-Br < Ti-I.
4. Conclusions
The important message of this work is that we have
structurallycharacterizedthelastmember,namelytheﬂuoro
complex,ofthe[Ti(η5-C5H5)2X2](X=halogenide)familyof
complexes. Although the preparation of 1 was reported ∼55
years ago, its exact molecular and crystal structure remained
unknown until our report in this work. Studies are now
underway in our laboratories to investigate the reactivity
patternof 1withbidentateandtridentateN-or/andO-based
ligands, and to study the hydrolytic behavior and cytotoxic
activities of the resulting products. It should be mentioned
that the ﬂuoride ions themselves, if present in the products,
are not cytotoxic at concentrations below 10−3 M[ 16].
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